Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03815643 · ClinicalTrials.gov registry record · Phase 3
Avelumab Program Rollover Study
A Phase 3 study of Solid Tumors, sponsored by EMD Serono Research & Development Institute.
- Active
- Registry status
- Phase 3
- Development phase
- 205
- Enrollment target
- 20
- Study locations
NCT03815643 is a Phase 3 study of Solid Tumors that is active but no longer recruiting, run by EMD Serono Research & Development Institute. The registered enrollment target is 205 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT03815643, a Phase 3 study of Solid Tumors, is active but no longer recruiting, sponsored by EMD Serono Research & Development Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 205 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
Conditions Studied
Interventions
- DRUG Avelumab
Study Locations (20)
Ohio
- University of Cincinnati - PARENT - Cincinnati
- Oncology Hematology Care - Cincinnati
- Oncology/Hematology Care Clinical Trials, LLC - Cincinnati
- OSU - James Comprehensive Cancer Center - Columbus
California
- University of California Davis Health System - Comprehensive Cancer Center - Sacramento
- Providence Medical Foundation - Santa Rosa
- St Joseph Heritage Healthcare - Santa Rosa
South Carolina
- Medical University of South Carolina (MUSC) - Charleston
- Greenville Hospital System University Medical Center (ITOR) - Upstate Affiliate Organization - Greenville
Arizona
- HonorHealth Research Institute - Scottsdale
Arkansas
- Highlands Oncology Group - Fayetteville
Connecticut
- Norwalk Hospital - The Whittingham Cancer Center - Norwalk
Florida
- Hematology - Oncology Associates of the Treasure Coast - Hematology-Oncology Associates of Treasure Coast - Port Saint Lucie
Georgia
- Northwest Georgia Oncology Centers - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2027-02-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03815643
The ClinicalTrials.gov registry entry for NCT03815643 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (28% lower). The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Avelumab is the first listed.
NCT03815643 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ohio, California, South Carolina.
Frequently Asked Questions
What is clinical trial NCT03815643 about?
NCT03815643 is a clinical study titled "Avelumab Program Rollover Study". The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
What is the current status of trial NCT03815643?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 205 participants. The study started on 2019-03-22. Estimated completion is 2027-02-19.
What conditions does trial NCT03815643 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT03815643?
The interventions under investigation include: Avelumab (DRUG).
Who is sponsoring clinical trial NCT03815643?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03815643 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
RECRUITING · Phase 3
-
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
ACTIVE NOT RECRUITING · Phase 3
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
RECRUITING · Phase 4
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.